Qurient acquires U.S. approval of Phase II clinical trial for MDR TB therapy Telacebec

Qurient(CEO Ki-Yeon Nam) announced a beginning of a Phase II clinical to globally develop a multi-drug resistant(MDR) tuberculosis(TB) therapy on the 17^th of July.

Qurient said the company will start the Phase II clinical trial for its First-in-Class MDR TB therapy Telacebec based on the Phase I clinical trial result completed in the U.S., and the early Phase II clinical trial will be conducte...